Provectus Biopharmaceuticals Inc. to Commence Series of Quarterly Conference Calls on Thursday, August 7, 2014
KNOXVILLE, Tenn. --(Business Wire)--
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT) ( http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, will begin a series of regular quarterly conference calls to update the market in general and shareholders in particular about developments at the Company. In the future, these calls will coincide with the filing of the Company's 10-Q and 10-K filings with the Securities and Exchange Commission as appropriate.
Craig Dees, PhD, CEO of Provectus, said, "As part of our drive for greater transparency, we have decided to hold conference calls to coincide with the filing of our 10-Q and 10-Ks with the SEC (News - Alert). If there is a material development in the future that warrants immediate discussion, we will naturally hold a special conference call rather than wait for the quarterly call."
Conference Call Thursday, August 7, 2014, at 4:00 PM EDT
The management of Provectus Biopharmaceuticals, Inc. will host a conference call on Thursday, August 7, 2014 at 4:00 PM Eastern. Those who wish to participate in the conference call may telephone 877-407-4019 from the U.S. International callers may telephone 201-689-8337, approximately 15 minutes before the call. A webcast will also be available at: www.pvct.com.
A digital replay will be available by telephone approximately two hours after the completion of the call until August 31, 2014, and may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for international callers, and using the Conference ID#13588317. |
